FDASmart Inc United States

Mrs Sheela Balani
CFO 

FEELIGREEN France

FEELIGREEN Feeligreen is a technology startup developing safe and effective micro-current devices for a wide range of dermo-therapeutic applications. Industry sectors Medtech Therapeutics Area Dermatology
Rheumatology
Your innovative solution

We incorporate semiconductor, microelectronics, bio-electronic and drug-formulation innovations into a technology platform from which we are already prototyping products that leap forward with unprecedented safety, ease-of-use and efficiency. Our initial in-vitro results demonstrate an ability to improve transdermic drug delivery by 4 to 10x on a large range of molecules.

Which problem are you solving ?

Targeted medical applications range from prevention of bedsores to controlled pain-relief and wound healing. Combined with advanced photo-dynamic therapy, we develop advanced solutions for dermatology. Our total addressable market is estimated to reach $7 billion by 2018.

Target market segments

Dermatology (psoriasis, atopic demartitis, labial herpes, acne, alopecia, ...) ; Pain relief (chronic pain, BTP, neuropathic and arthritic pain) ; Bedsores (bedsore prevention, bedsore detection , chronic wounds)

Key value proposition

Security and Safety / Controlled Drug Delivery / Programmable-Remote bolus / Measure of compliance

Dr CHRISTOPHE BIANCHI
Dr CHRISTOPHE BIANCHI
CEO 

Feinstein Lab of Neurogenetics United States

Research Interest:

  • Using targeted mutagenesis and mouse genetics to study how the brain functions.
    The brain interprets the world through five major modalities of sensation.
    Information for sight, sound, taste and touch are relayed to the brain through networks of cellular or neuronal connections.

    The sense of smell (olfaction); however, uses specialized bipolar neurons, which can simultaneously identify odors with their dendritically located cilia and make direct connections to the brain with their axonal projections. Thus, olfactory neurons directly convert stimuli from the external world into an internal representation within the brain. In a surprising twist, the same protein (the odorant receptor) that is used for identifying odors is also used for guiding the axonal connection to the brain. The olfactory system detects the universe of odors through ~1000 different odorant receptor coding genes. But, each olfactory neuron makes only one type of odorant receptor. The distribution of neuron types is scattered across the interior lining of the nose, but their axonal projections to the brain are sorted out into discrete units that represent each neuronal type.

    To examine how the odorant receptor (OR) functions in odor detection and axonal projections, I have used mouse embryonic stem cell technology coupled with genetic manipulation to alter the expressed OR proteins. Studying these modified OR proteins in vivo, I have found that several additional processes within the neuron are affected. The observed one OR gene expressed per olfactory neuron is maintained even if additional OR genes are added to the genome. I am interested in understanding how olfactory neurons control OR gene expression and how the OR protein provides specificity for axonal projections to form discrete units in the brain.
Dr CHARLOTTE D'Hulst
Post Doctoral Research Fellow 

Felicitex Therapeutics United States

Felicitex Therapeutics is a drug discovery company at the forefront of one of the most promising areas in oncology –quiescent (sleeping) cancer cells. We are developing treatments and diagnostic assays to improve the effectiveness and long-term outcomes of treatments for the deadliest and most therapy resistant cancers: pancreatic, colorectal, non-small cell lung, and ovarian.

 

Recently, it has become accepted in the scientific community that populations of malignant cells are not homogenous, they have hierarchy.  Some of the cancer cells divide rapidly but some do not, some of the cancer cells are sleeping. They are in the quiescent state. This is especially true of solid tumors in which the cells in the outer layers are proliferating, but the inner volume comprises a large proportion of quiescent cells, frequently as a result of inadequate nutrient supply and oxygen deprivation (hypoxia). Hypoxic regions have long been known to be resistant to chemotherapy and radiation treatment. Tumor hypoxia, as a target for chemotherapy, is currently an active area of research.

 

Moreover, when cancer cells are under stress from either chemotherapy, anti-angiogenesis therapy, specific targeted treatment, or radiation, cancer cells often go to “sleep”, or use quiescent as a niche to hide.  After the completion of treatment, these cells can acquire resistance to the current treatment, begin growing and cause cancer recurrence. This process is called pharmacological quiescence.

Dr Maria Vilenchik
CEO 

FIRALIS France

Firalis  Firalis offers a wide spectrum of biomarker services from discovery to the clinical qualification Industry sectors Biotech Therapeutics Area Cardiology / Vascular Diseases
Rare Disease
Rheumatology
Your innovative solution

Firalis has developed an integrated platform in its own laboratory located in Huningue, France. The platform includes a clinical testing laboratory, an assay development laboratory and a production site for critical reagents. The company is striving to develop bioanalytical tools such as antibodies, assay kits or microarrays that are meeting the highest standards of quality. The process leading to the design and production of these products is compliant with ISO 13485 standards, the international norm for medical devices

Which problem are you solving ?

With a comprehensive expertise in the field, Firalis develops biomarkers and biomarker-based diagnostic kits to improve disease outcomes, patient comfort and therapeutic decisions; finally to generate remarkable savings in healthcare, which is the principal goal of biomarker services offered by Firalis. Our activities mainly but not exclusively involve biomarkers that are related to inflammatory disorders including common diseases such as atherosclerosis, rheumatoid arthritis or rare/orphan diseases such as systemic or autoimmune vasculitis

Target market segments

The services consist of biomarker R&D programs for clients such as pharmaceutical companies, biotechnology companies and public laboratories.

Key value proposition

Novel values via biomarkers, discovery, cutting-edge platform, high quality standard

TONY YAACOUB
CHIEF BUSINESS OFFICER 

Fox Rothschild United States

Fox Rothschild LLP is a national law firm with more than 600 attorneys practicing in 21 offices coast to coast. We’ve been serving clients for more than a century, and we’ve been climbing the ranks of the nation’s largest firms for many years, according to both The Am Law 100 and The National Law Journal. 

Our lawyers provide a full range of legal services to public and private companies – from family-run businesses to multinational corporations. We also represent charitable, medical and educational institutions both in the United States and in more than 50 countries worldwide.

We’re smart. We’re solid. We’re established. But we believe we’re also a bit different from many other law firms — and we’re proud of it.

We’re entrepreneurial. We’re resourceful. We’re nimble. It’s those qualities that clients tell us they value in their lawyers — and that have allowed us to build a firm of bright, creative, responsive attorneys with solid legal know-how and valuable industry experience.

Our lawyers partner with clients and work hand-in-hand with them to keep pace with their business objectives and anticipate the challenges ahead. Our entrepreneurial approach — as a firm that works in the trenches with clients, helping them to achieve their goals — is a characteristic that differentiates us. When you choose Fox, you gain an advisor that will be as dedicated to your success as you are.

Mr Shahnam Sharareh
Attorney 

French Bio Beach United States

French BioBeach is a Life Science Catalyst between France & Southern California, Enabling and Fostering Business Relationships. We work with SoCal companies on their European Expansion and with French companies on their US expansion. We facilitate Partnering Opportunities and/or Physical Implantation (incubator).

Dr Stephane Richard

French Embassy United States

Dr Sarah Crochon
Biotech & Health Industry Attaché 

French-American Biotech Springboard United States

WHO WE ARE The French-American Biotechnology Springboard (FABS) is a steering committee developed in collaboration with the French-American Chamber of Commerce of New England [FACCNE] to guide French Bio-Entrepreneurs in the highly specific scientific, business and cultural New England environment. The Group is comprised of American and French professional volunteers with complementary backgrounds and competencies, who have had and/or are currently holding positions in Massachusetts-based Biotechnology and Pharmaceutical Companies.   WHAT WE DO -Mentoring French companies that are evaluating or have decided to start their business in the New England. -Guiding the French Bio-Entrepreneurs first installation steps, sharing their experience and expertise and facilitates their development by leveraging the local expertise of a dynamic network of professionals. -Supporting FACCNE life sciences activities with a yearly FACCNE Biotech meeting in March. -Coaching start ups/Institutions to better prepared to the US market during French biotech tours (presentations, one on one coaching). -Helping US Companies to explore / connect with French market through participation to programs such as the Boston based Office for Science and Technology - accelerator designed to help entrepreneurs grow their business in France and Europe.

Dr Gigi Shafai
Startup Advisor and Mentor 

Freyeur & Trogue United States

Fosters, develops and commercializes healthcare and life sciences technology.

Mark Goldstone
CEO